Ignite Creation Date:
2024-05-06 @ 12:12 PM
Last Modification Date:
2024-10-26 @ 12:55 PM
Study NCT ID:
NCT03704077
Status:
WITHDRAWN
Last Update Posted:
2020-05-19
First Post:
2018-10-09
Brief Title:
An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Randomized Active-Controlled Open-Label Phase 2 Clinical Trial of BMS-986213 in Combination With Various Standard-of-Care Therapeutic Regimens in Participants With Recurrent Locally Advanced or Metastatic Gastric Cancer GC or Gastroesophageal Junction GEJ Adenocarcinoma
Status:
WITHDRAWN
Status Verified Date:
2020-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Replaced it with another clinical trial
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the effectiveness of relatlimab plus nivolumab alone or in combination with various standard-of-care treatments in participants with gastric cancer GC or gastroesophageal junction GEJ adenocarcinoma that has come back or spread to other places in the body after prior therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2018-001070-20 | EUDRACT_NUMBER | None | None |